Thus, larger cohorts are needed that consist of non-insulin-resistant, prediabetes (impaired fasting blood glucose and/or impaired insulin tolerance), and T2D patients to support the decline in TAS1R3 with the progression of insulin resistance. This evidence concerns the gene INS and type 2 diabetes mellitus.